Smith & Nephew Plc SNN 深 滬
等待開盤 09-19 09:30:00 美东时间
36.985
-0.325
-0.87%
華盛通- 最 高37.15
- 今 開37.03
- 成交量 31.41万股
- 最 低 36.92
- 昨 收 37.31
- 總市值 161.99亿
- 52周最高 38.79
- 市盈率 靜 39.30
- 換手率 0.07%
- 52周最低 23.243
- 委 比 -62.67%
- 總股本 4.38亿
- 歷史最高 48.168
- 量 比 0.38
- 振 幅 0.62%
- 歷史最低 8.968
- 每 手 1
- 風險率 3.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多重磅！不用英伟达GPU ！中科院类脑脉冲大模型“瞬悉1.0”用国产GPU实现训练效率提升百倍！
（来源：电子创新网） 据中国科学院官网信息，近日，中国科学院自动化研究所李国齐和徐波团队与相关单位合作，推出类脑脉冲大模型“瞬悉1.0”（SpikingBra...
09-18 09:20
Smith & Nephew Announces Share Sale by Executive
Smith & Nephew Snats ( ($SNN) ) has provided an update. On September 9, 202...
09-10 01:58
What Does the Market Think About Smith & Nephew?
Smith & Nephew's (NYSE:SNN) short percent of float has risen 6.56% since it...
09-04 04:00
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
<p>Smith+Nephew has launched the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma to promote wound healing. The system is designed for chronic exuding wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. It is CMS-covered for diabetic patients with chronic wounds under certain conditions. The system can be tailored for wound shape and depth with a single bl...
09-03 14:16
Smith & Nephew Grants Share Awards to Executive
Smith & Nephew Snats ( ($SNN) ) has provided an announcement. On August 27,...
08-30 00:47
Smith+Nephew Appoints Dr. Garheng Kong as Non-Executive Director
Smith & Nephew Snats ( ($SNN) ) has shared an announcement. On August 28, 2...
08-28 18:57
Smith & Nephew Aligns Director Compensation with Shareholder Interests
An update from Smith & Nephew Snats ( ($SNN) ) is now available. On August ...
08-27 00:57
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
Sionna Therapeutics initiated a Phase 1 trial evaluating SION-451, a first-in-class NBD1 stabilizer, in combination with SION-2222 and SION-109 for cystic fibrosis treatment. The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers, with topline data expected mid-2026. Sionna seeks to revolutionize CF treatment by targeting CFTR dysfunction via NBD1 stabilization, addressing an unmet need for therapies that direct...
08-25 11:00
Canaccord Genuity Maintains Hold on Smith & Nephew, Raises Price Target to $36
Canaccord Genuity analyst Caitlin Cronin maintains Smith & Nephew (NYSE:SNN) with a Hold and raises the price target from $28 to $36.
08-18 20:11
BlackRock Adjusts Holdings in Smith & Nephew
Smith & Nephew Snats ( ($SNN) ) has issued an announcement. On August 1, 20...
08-08 04:17
